Back to today’s briefing

Story perspectives

Breakthrough CAR-T Therapy Achieves 72.7% Remission Rate!

5/31/2025

46 6

Summary

Story summary

In an exciting breakthrough, researchers at Washington University School of Medicine have unveiled WU-CART-007, an innovative CAR-T cell therapy targeting aggressive blood cancers. In a Phase 1/2 trial involving 28 patients with relapsed T-ALL or T-LBL, an impressive 72.7% achieved complete remission, offering hope for those battling these high-risk conditions.

1 of 1

Story summary

In an exciting breakthrough, researchers at Washington University School of Medicine have unveiled WU-CART-007, an innovative CAR-T cell therapy targeting aggressive blood cancers. In a Phase 1/2 trial involving 28 patients with relapsed T-ALL or T-LBL, an impressive 72.7% achieved complete remission, offering hope for those battling these high-risk conditions.